ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. An Actriia Fusion Protein Got Fda Approved For Pah Treatment
News Feed
course image
  • 02 Apr 2024
  • Admin
  • News Article

An ActRIIA Fusion Protein Got FDA Approved for PAH Treatment

Overview

On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment. PAH, characterized by elevated blood pressure in the arteries connecting the heart and lungs, poses a grave risk of heart failure. While pulmonary vasodilators have improved patient prognosis, the challenge of disease progression persists, underscoring the importance of innovative treatments like Sotatercept.

Sotatercept’s Mechanism of Action

  • Sotatercept introduces a novel paradigm in PAH therapy. 
  • It functions as a fusion protein, incorporating the binding site of ACVR2A, thereby disrupting downstream signaling pathways, particularly the SMAD pathway. 
  • By sequestering activin, a member of the TGF-β superfamily, Sotatercept reinstates the equilibrium between growth-promoting and growth-inhibiting pathways within the pulmonary arteries.

ACVR2A: Implications Across Disease Spectrum

  • Beyond its role in PAH, ACVR2A emerges as a pivotal player in the pathogenesis of various ailments. 
  • This broad implication positions ACVR2A targeting as a promising strategy in arresting disease progression. 
  • Alongside Sotatercept, two other pharmaceutical pipelines are on the cusp of market approval, while six companies are advancing drugs targeting ACVR2A in preclinical phases, addressing conditions ranging from cancer to myelofibrosis.

Sino Biological's Offering to Support Pah Research

The pursuit of PAH therapeutics primarily revolves around targeting an array of molecular pathways, including ACVRs, BRD4, NF-kB, Nrf2, NFE2L1/Nrf1, mTOR, ASK-1, mineralocorticoid receptor, estrogen receptor, CD20, calcineurin, IL-6R, leukotriene A4 hydrolase, tryptophanhydrolase, and endothelial progenitor cells. 

  • Sino Biological plays a pivotal role in this endeavor by supplying recombinant proteins, antibodies, cytokines, and growth factors, catering to diverse research needs across various stages of PAH drug development.

Sino Biological 

As a leading provider of comprehensive solutions and innovative tools used to advance life science and improve human health, Sino Biological is proud to offer premium products to support researchers in their quest to unlock novel treatments and improve patient outcomes.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form